{"filing":{"accession_number":"0001104659-26-091625","cik":"0001446847","ticker":"IRWD","company_name":"IRONWOOD PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tm2622244d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/tm2622244d1_8k.htm"},"events":[{"id":25404,"run_id":23057,"accession_number":"0001104659-26-091625","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Ironwood Pharmaceuticals disclosed Q2 2026 financial results with total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million, along with raised full-year 2026 guidance for U.S. LINZESS net sales ($1.15–$1.20 billion), total revenue ($460–$485 million), and adjusted EBITDA (\u003e$310 million).","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26226,"accession_number":"0001104659-26-091625","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Ironwood Pharmaceuticals. The press release reports total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million for Q2 2026, along with raised full-year 2026 guidance for U.S. LINZESS net sales ($1.15-$1.20 billion), total revenue ($460-$485 million), and adjusted EBITDA (\u003e$310 million). The filing is properly classified under Item 2.02 and the exhibit is a standard earnings press release with detailed financial tables and business highlights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:15.515386+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26226,"accession_number":"0001104659-26-091625","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Ironwood Pharmaceuticals. The press release reports total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million for Q2 2026, along with raised full-year 2026 guidance for U.S. LINZESS net sales ($1.15-$1.20 billion), total revenue ($460-$485 million), and adjusted EBITDA (\u003e$310 million). The filing is properly classified under Item 2.02 and the exhibit is a standard earnings press release with detailed financial tables and business highlights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:15.515386+00:00","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-08-06"}]}